Eva Segelov was appointed as Professor and Director of Oncology at Monash Health and Monash University in February 2017. She is an Honorary Associate of the NHMRC Clinical Trials Centre, Sydney Medical School and Honorary Professor at Shanghai Jiatong University; previously Associate Professor at the University of New South Wales and Senior Medical Oncologist at St Vincent’s Hospital, Sydney. She is a recognised national and international expert in the fields of gastrointestinal cancer, including neuroendocrine tumours, and breast cancer, with a 20 year history of management of patients in a multidisciplinary setting.
Professor Segelov is an active member of the Australian Gastrointestinal Trials Group (AGITG), serving as a Board Member and Convenor of the Annual Scientific Meeting 2014-2018. She is the co-founder of the Commonwealth Neuroendocrine Tumour Society (CommNETS), an international research collaborative; Chair of the Gastrointestinal Group of the Clinical Oncological Society of Australia (COSA); faculty group member of the European Society of Medical Oncology (ESMO) CUP, Endocrine Tumours, and Others group and the Gastrointestinal Faculty Group; IDMSC member for Transtasman Oncology Group (TROG). She is an Associate Editor of the Journal of Global Oncology (ASCO) and Guest Editor of the Inaugural Special Edition of Journal of Global Oncology “Cancer in Indigenous Communities”. Eva serves on the ESMO Annual Scientific Meeting subcommittee Neuroendocrine and Endocrine cancer and is a member of the conference organizing committee for the inaugural ASCO “Breakthrough: A Global Summit for Oncology Innovators meeting” conference’; she was co-Track Chair of Gastrointestinal Cancer for the 2017 ESMO Asia Annual Scientific Meeting.
Professor Segelov has led multiple national and international Oncology clinical trials, including investigator-initiated studies. Her research interests relate to translational studies of targeted therapies in defined subpopulations to increase benefit and reduce the toxicity of cancer treatments; new anticancer therapies and understanding the molecular changes induced by anticancer therapy. She has published over 150 articles, expert reviews, book chapters and has edited three books. She is an NHMRC grant assigner and reviews grants, manuscripts and theses for multiple international organisations. Eva is a frequent invited speaker at national and international conferences as well as community events, in particular the “Dr Hope” fund which raises money for Oncology Clinical Trials at Monash Health. She is a panel member of the Australasian L’Oréal-UNESCO for Women in Science Jury. Professor Segelov has a particular interest in professional development using innovative learning techniques, for which she was awarded the UNSW Vice Chancellors Award for Teaching Excellence in 2006. She developed the Seminal Advances Preceptorship in Cancer program which she facilitates for multiple Australasian collaborative trials groups.